Hepatocellular Carcinoma Drug Market Report

Global and Region Hepatocellular Carcinoma Drug Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 01, 2022
  • PAGES：204
  • REPORT CODE：GMM974989
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Hepatocellular Carcinoma Drug is a drug for treating Hepatocellular Carcinoma.

    The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Hepatocellular Carcinoma Drug in US$ by following Product Segments.: Chemotherapy, Brachytherapy and Ablation Therapy.Company profiles are primarily based on public domain information including companyJohnson & JohnsonTeva PharmaceuticalKingond PharmCSPCSigma-Tau GroupNovartisJohnson & JohnsonSun PharmaceuticalFudan-ZhangjiangLuye PharmaGilead Sciences

    The report details the trend, potential and market size of Hepatocellular Carcinoma Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Hepatocellular Carcinoma Drugmarket, defines the market attractiveness level of Hepatocellular Carcinoma Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Hepatocellular Carcinoma Drug industry, describes the types of Hepatocellular Carcinoma Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global Hepatocellular Carcinoma Drug market and the development prospects and opportunities of Hepatocellular Carcinoma Drug industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Hepatocellular Carcinoma Drug market in Chapter 13.

    By Player:

    • Pacira

    • Teva Pharmaceutical

    • Kingond Pharm

    • CSPC

    • Sigma-Tau Group

    • Novartis

    • Johnson & Johnson

    • Sun Pharmaceutical

    • Fudan-Zhangjiang

    • Luye Pharma

    • Gilead Sciences

    By Type:

    • Chemotherapy

    • Brachytherapy

    • Ablation Therapy

    By End-User:

    • Surgical Resection

    • Liver Transplantation

    • Ablation

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Hepatocellular Carcinoma Drug Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Hepatocellular Carcinoma Drug Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Hepatocellular Carcinoma Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Hepatocellular Carcinoma Drug Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Hepatocellular Carcinoma Drug Market Analysis and Outlook to 2022

    • 7.1 Global Hepatocellular Carcinoma Drug Consumption (2017-2022)

    • 7.2 United States Hepatocellular Carcinoma Drug Consumption (2017-2022)

    • 7.3 Europe Hepatocellular Carcinoma Drug Consumption (2017-2022)

    • 7.4 China Hepatocellular Carcinoma Drug Consumption (2017-2022)

    • 7.5 Japan Hepatocellular Carcinoma Drug Consumption (2017-2022)

    • 7.6 India Hepatocellular Carcinoma Drug Consumption (2017-2022)

    • 7.7 South Korea Hepatocellular Carcinoma Drug Consumption (2017-2022)

    8 Region and Country-wise Hepatocellular Carcinoma Drug Market Analysis and Outlook to 2028

    • 8.1 Global Hepatocellular Carcinoma Drug Consumption Forecast (2022-2028)

    • 8.2 United States Hepatocellular Carcinoma Drug Consumption Forecast (2022-2028)

    • 8.3 Europe Hepatocellular Carcinoma Drug Consumption Forecast (2022-2028)

    • 8.4 China Hepatocellular Carcinoma Drug Consumption Forecast (2022-2028)

    • 8.5 Japan Hepatocellular Carcinoma Drug Consumption Forecast (2022-2028)

    • 8.6 India Hepatocellular Carcinoma Drug Consumption Forecast (2022-2028)

    • 8.7 South Korea Hepatocellular Carcinoma Drug Consumption Forecast (2022-2028)

    9 Global Hepatocellular Carcinoma Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Hepatocellular Carcinoma Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Chemotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Brachytherapy Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Ablation Therapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Hepatocellular Carcinoma Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Surgical Resection Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Liver Transplantation Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ablation Consumption and Growth Rate (2017-2022)

    10 Global Hepatocellular Carcinoma Drug Market Outlook by Types and Applications to 2028

    • 10.1 Global Hepatocellular Carcinoma Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Brachytherapy Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Ablation Therapy Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Hepatocellular Carcinoma Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Surgical Resection Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Liver Transplantation Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Ablation Consumption Forecast and Growth Rate (2022-2028)

    11 Global Hepatocellular Carcinoma Drug Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Hepatocellular Carcinoma Drug Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Hepatocellular Carcinoma Drug Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Hepatocellular Carcinoma Drug Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Hepatocellular Carcinoma Drug Market Competitive Analysis

    • 14.1 Pacira

      • 14.1.1 Pacira Company Details

      • 14.1.2 Pacira Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Pacira Hepatocellular Carcinoma Drug Product and Service

    • 14.2 Teva Pharmaceutical

      • 14.2.1 Teva Pharmaceutical Company Details

      • 14.2.2 Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Teva Pharmaceutical Hepatocellular Carcinoma Drug Product and Service

    • 14.3 Kingond Pharm

      • 14.3.1 Kingond Pharm Company Details

      • 14.3.2 Kingond Pharm Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Kingond Pharm Hepatocellular Carcinoma Drug Product and Service

    • 14.4 CSPC

      • 14.4.1 CSPC Company Details

      • 14.4.2 CSPC Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 CSPC Hepatocellular Carcinoma Drug Product and Service

    • 14.5 Sigma-Tau Group

      • 14.5.1 Sigma-Tau Group Company Details

      • 14.5.2 Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Sigma-Tau Group Hepatocellular Carcinoma Drug Product and Service

    • 14.6 Novartis

      • 14.6.1 Novartis Company Details

      • 14.6.2 Novartis Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Novartis Hepatocellular Carcinoma Drug Product and Service

    • 14.7 Johnson & Johnson

      • 14.7.1 Johnson & Johnson Company Details

      • 14.7.2 Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Johnson & Johnson Hepatocellular Carcinoma Drug Product and Service

    • 14.8 Sun Pharmaceutical

      • 14.8.1 Sun Pharmaceutical Company Details

      • 14.8.2 Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Sun Pharmaceutical Hepatocellular Carcinoma Drug Product and Service

    • 14.9 Fudan-Zhangjiang

      • 14.9.1 Fudan-Zhangjiang Company Details

      • 14.9.2 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product and Service

    • 14.10 Luye Pharma

      • 14.10.1 Luye Pharma Company Details

      • 14.10.2 Luye Pharma Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Luye Pharma Hepatocellular Carcinoma Drug Product and Service

    • 14.11 Gilead Sciences

      • 14.11.1 Gilead Sciences Company Details

      • 14.11.2 Gilead Sciences Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Gilead Sciences Hepatocellular Carcinoma Drug Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Hepatocellular Carcinoma Drug

    • Figure Hepatocellular Carcinoma Drug Picture

    • Table Global Hepatocellular Carcinoma Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Hepatocellular Carcinoma Drug Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Hepatocellular Carcinoma Drug Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Hepatocellular Carcinoma Drug Consumption by Country (2017-2022)

    • Figure United States Hepatocellular Carcinoma Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Hepatocellular Carcinoma Drug Consumption and Growth Rate (2017-2022)

    • Figure China Hepatocellular Carcinoma Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Hepatocellular Carcinoma Drug Consumption and Growth Rate (2017-2022)

    • Figure India Hepatocellular Carcinoma Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Hepatocellular Carcinoma Drug Consumption and Growth Rate (2017-2022)

    • Figure Global Hepatocellular Carcinoma Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Hepatocellular Carcinoma Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Hepatocellular Carcinoma Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Hepatocellular Carcinoma Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Hepatocellular Carcinoma Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Hepatocellular Carcinoma Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Hepatocellular Carcinoma Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chemotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Brachytherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Ablation Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Surgical Resection Consumption and Growth Rate (2017-2022)

    • Figure Global Liver Transplantation Consumption and Growth Rate (2017-2022)

    • Figure Global Ablation Consumption and Growth Rate (2017-2022)

    • Figure Global Chemotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Brachytherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ablation Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Surgical Resection Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Liver Transplantation Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ablation Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Hepatocellular Carcinoma Drug Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Hepatocellular Carcinoma Drug Export by Region (Top 5 Countries) (2017-2028)

    • Table Pacira (Foundation Year, Company Profile and etc.)

    • Table Pacira Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pacira Hepatocellular Carcinoma Drug Product and Service

    • Table Teva Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Teva Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceutical Hepatocellular Carcinoma Drug Product and Service

    • Table Kingond Pharm (Foundation Year, Company Profile and etc.)

    • Table Kingond Pharm Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Kingond Pharm Hepatocellular Carcinoma Drug Product and Service

    • Table CSPC (Foundation Year, Company Profile and etc.)

    • Table CSPC Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table CSPC Hepatocellular Carcinoma Drug Product and Service

    • Table Sigma-Tau Group (Foundation Year, Company Profile and etc.)

    • Table Sigma-Tau Group Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sigma-Tau Group Hepatocellular Carcinoma Drug Product and Service

    • Table Novartis (Foundation Year, Company Profile and etc.)

    • Table Novartis Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Hepatocellular Carcinoma Drug Product and Service

    • Table Johnson & Johnson (Foundation Year, Company Profile and etc.)

    • Table Johnson & Johnson Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Hepatocellular Carcinoma Drug Product and Service

    • Table Sun Pharmaceutical (Foundation Year, Company Profile and etc.)

    • Table Sun Pharmaceutical Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sun Pharmaceutical Hepatocellular Carcinoma Drug Product and Service

    • Table Fudan-Zhangjiang (Foundation Year, Company Profile and etc.)

    • Table Fudan-Zhangjiang Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Fudan-Zhangjiang Hepatocellular Carcinoma Drug Product and Service

    • Table Luye Pharma (Foundation Year, Company Profile and etc.)

    • Table Luye Pharma Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Luye Pharma Hepatocellular Carcinoma Drug Product and Service

    • Table Gilead Sciences (Foundation Year, Company Profile and etc.)

    • Table Gilead Sciences Hepatocellular Carcinoma Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences Hepatocellular Carcinoma Drug Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US